Daniel Pariser has more than 25 years of experience in mass tort, class action, and product liability litigation in federal and state courts at both the trial court and appellate levels. He has a specific focus on representing health care industry clients in complex products liability matters and related litigation. He frequently handles significant mass tort litigation spanning multiple jurisdictions, overseeing strategy and coordinating teams of lawyers. He also often advises clients on product liability risk mitigation strategies. Daniel also represents health care industry clients in government enforcement actions, commercial litigation, antitrust litigation and internal investigations. Daniel is nationally ranked by Chambers in Product Liability and Mass Torts, with clients commenting that "[h]e has a great combination of intellect, tactical knowledge and tenacity to pursue issues" and is "capable of distilling complex concepts into language that is acceptable to a jury." Daniel is a graduate of the University of Pennsylvania, 1994, summa cum laude, and Harvard Law School, 1998, magna cum laude.
Experience
- Sanofi as national counsel in product liability litigation concerning Zantac. Appointed to defense steering committee in In re Zantac (ranitidine) Prods. Liab. Litig., MDL No. 2924 (S.D. Fla.).
- Hologic as lead counsel in product liability litigation concerning the BioZorb marker. In re: BioZorb Device Prods. Liab. Litig., Case No. 1:22-cv-11895 (D. Mass).
- Bristol-Myers Squibb and Sanofi as national counsel in product liability litigation concerning Plavix®. Argued and won summary judgment in bellwether MDL case on learned intermediary grounds after obtaining favorable prescribing physician testimony. See In re Plavix Mktng., Sales Prac. and Prods. Liability Litig., MDL No. 2418, 2017 WL 3531684 (D.N.J. 2017).
- Sanofi as national counsel in product liability litigation concerning thalidomide.
- Cynosure in purported consumer fraud class action concerning laser device. Argued and prevailed on summary judgment. Plastic Surgery Associates, S.C. v. Cynosure, Inc., 407 F. Supp. 3d 59 (D. Mass. 2019).
- Bristol-Myers Squibb in appeal affirming dismissal with prejudice of wrongful death claim under Twombly/Iqbal. Rollins v. Wackenhut Services, Inc., et al. 703 F.3d 122 (D.C. Cir. 2012).
- Bristol-Myers Squibb and Sanofi on successful motion to dismiss claim by third-party payor seeking reimbursement of prescription drug costs. Employer Teamsters-Local Nos. 175/505 Health and Welfare Trust Fund v.Bristol-Myers Squibb Company et al., 969 F. Supp.2d 463 (S.D.W.Va 2013).
- GlaxoSmithKline in antitrust litigation alleging that company filed "sham" patent litigation.
- GlaxoSmithKline in case alleging antitrust violations and breach of contract arising from licensing agreement.
- Pharmaceutical company in state attorney general consumer protection litigation.
- Pharmaceutical company in multidistrict litigation involving tens of thousands of suits. Managed discovery proceedings nationwide.
- Senior executive of FORTUNE 500 company in criminal investigation.
Perspectives
Recognition
Credentials
Education
- J.D., Harvard Law School, 1998, magna cum laude
- B.A., University of Pennsylvania, 1994, summa cum laude
Admissions
- District of Columbia
- New York
- Supreme Court of the United States
- U.S. Court of Appeals for the District of Columbia Circuit
- U.S. Court of Appeals for the Second Circuit
- U.S. Court of Appeals for the Third Circuit
- U.S. Court of Appeals for the Fourth Circuit
- U.S. Court of Appeals for the Fifth Circuit
- U.S. Court of Appeals for the Ninth Circuit
- U.S. Court of Appeals for the Eleventh Circuit
Activities
- Sustaining Member, Product Liability Advisory Council (PLAC)
- Member, DRI
- Judge, 2024 Colonial Classic X Mock Trial Tournament, Williamsburg, VA. (Oct. 27, 2024)